MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/115/0.1/20.06.25 | Market Closed - Bid/Ask 06:20:12 01/07/2024 pm IST | After market 11:35:38 pm | |||
| 3.59 EUR | -1.37% |
|
3.765 | +4.87% |
| Current month | +25.52% | ||
| 1 month | +24.66% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 01/24/01 | 3.59 | -1.37% |
| 28/24/28 | 3.64 | -1.36% |
| 27/24/27 | 3.69 | +0.27% |
| 26/24/26 | 3.68 | -4.66% |
| 25/24/25 | 3.86 | +10.60% |
Delayed Quote Börse Stuttgart
Last update July 01, 2024 at 06:20 pm IST
More quotesStatic data
| Product type | Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | ME1GB4 |
| ISIN | DE000ME1GB44 |
| Date issued | 03/10/2023 |
| Strike | 115 $ |
| Maturity | 20/06/2025 (354 Days) |
| Parity | 10 : 1 |
| Emission price | 0.97 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.86 € |
|---|---|
| Lowest since issue | 0.79 € |
| Delta | 0.83x |
| Omega | 2.961 |
| Premium | 6.86x |
| Gearing | 3.58x |
| Moneyness | 1.267 |
| Difference Strike | -30.45 $ |
| Difference Strike % | -26.48% |
| Spread | 0.01 € |
| Spread % | 0.26% |
| Theoretical value | 3.785 |
| Implied Volatility | 35.87 % |
| Total Loss Probability | 26.86 % |
| Intrinsic value | 2.849 |
| Present value | 0.9360 |
| Break even | 155.60 € |
| Theta | -0.02x |
| Vega | 0.03x |
| Rho | 0.07x |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
950.4
DKK
Spread / Average Target
-5.49%
- Stock Market
- Warrants
- Warrant
